AIM AND BACKGROUND: The aim of this study is to analyze the main clinical and pathologic characteristics of radiation-induced breast carcinomas (BC) following treatment for Hodgkin's disease (HD) and to identify the risk factors for their induction. To create a mathematical model for the prediction of expected age at which a BC might develop based on the age at treatment for HD. MATERIALS AND METHODS: Thirty-nine cases of women with BC that developed after treatment for HD in puberty or adolescence were analyzed retrospectively. The median age at initiation of treatment for HD was 12.9 years (9-21). The median age at diagnosis of the second malignancy - breast carcinoma was 32.4 years (22.9-39). RESULTS: THE DISTRIBUTION OF PATIENTS ACCORDING TO THE CLINICAL T STAGE OF BREAST CANCER WAS AS FOLLOWS: 11 patients with T1 stage BC (28%), 22 with T2 stage (56%) and 6 with stage T3 (16%). Prevalent were tumors localized in the lateral breast quadrants. The observed 5 year survival was 95%. CONCLUSION: The risk of solid tumors, especially breast cancer, is high among women with HD disease who were treated with radiotherapy in their childhood. In this article, we propose a specific mathematical age formula which could be used as predictive equation when the age of the treatment for HD is in the range between 9 and 21 years. Systematic screening for breast cancer in these patients would be significantly important for their health and could improve their survival.
AIM AND BACKGROUND: The aim of this study is to analyze the main clinical and pathologic characteristics of radiation-induced breast carcinomas (BC) following treatment for Hodgkin's disease (HD) and to identify the risk factors for their induction. To create a mathematical model for the prediction of expected age at which a BC might develop based on the age at treatment for HD. MATERIALS AND METHODS: Thirty-nine cases of women with BC that developed after treatment for HD in puberty or adolescence were analyzed retrospectively. The median age at initiation of treatment for HD was 12.9 years (9-21). The median age at diagnosis of the second malignancy - breast carcinoma was 32.4 years (22.9-39). RESULTS: THE DISTRIBUTION OF PATIENTS ACCORDING TO THE CLINICAL T STAGE OF BREAST CANCER WAS AS FOLLOWS: 11 patients with T1 stage BC (28%), 22 with T2 stage (56%) and 6 with stage T3 (16%). Prevalent were tumors localized in the lateral breast quadrants. The observed 5 year survival was 95%. CONCLUSION: The risk of solid tumors, especially breast cancer, is high among women with HD disease who were treated with radiotherapy in their childhood. In this article, we propose a specific mathematical age formula which could be used as predictive equation when the age of the treatment for HD is in the range between 9 and 21 years. Systematic screening for breast cancer in these patients would be significantly important for their health and could improve their survival.
Entities:
Keywords:
Breast cancer; Hodgkin's disease; Risk factors
Authors: R Maurizi Enrici; A P Anselmo; M F Osti; M Santoro; V Tombolini; F Mandelli; C Biagini Journal: Haematologica Date: 1997 Jan-Feb Impact factor: 9.941
Authors: A J Janov; M Tulecke; A O'Neill; S Lester; P M Mauch; J Harris; S J Schnitt; C L Shapiro Journal: Breast J Date: 2001 Jan-Feb Impact factor: 2.431
Authors: A Tinger; T H Wasserman; E E Klein; E A Miller; T Roberts; J V Piephoff; N A Kucik Journal: Int J Radiat Oncol Biol Phys Date: 1997-03-01 Impact factor: 7.038
Authors: E Salloum; R Doria; W Schubert; D Zelterman; T Holford; K B Roberts; L R Farber; R K Kiehl; J Cardinale; D L Cooper Journal: J Clin Oncol Date: 1996-09 Impact factor: 44.544
Authors: R Sankila; S Garwicz; J H Olsen; H Döllner; H Hertz; A Kreuger; F Langmark; M Lanning; T Möller; H Tulinius Journal: J Clin Oncol Date: 1996-05 Impact factor: 44.544
Authors: J Yahalom; J A Petrek; P W Biddinger; S Kessler; D D Dershaw; B McCormick; M P Osborne; D A Kinne; P P Rosen Journal: J Clin Oncol Date: 1992-11 Impact factor: 44.544
Authors: S Bhatia; L L Robison; O Oberlin; M Greenberg; G Bunin; F Fossati-Bellani; A T Meadows Journal: N Engl J Med Date: 1996-03-21 Impact factor: 91.245
Authors: F E van Leeuwen; W J Klokman; A Hagenbeek; R Noyon; A W van den Belt-Dusebout; E H van Kerkhoff; P van Heerde; R Somers Journal: J Clin Oncol Date: 1994-02 Impact factor: 44.544